Tag: M.W=350-400

Huang, Shuai-hao published the artcileComparison of analgesia effect of non-steroidal anti-inflammatory drugs after posterior lumbar fusion surgery, Application In Synthesis of 198470-85-8, the publication is Shiyong Yixue Zazhi (2014), 30(20), 3321-3323, database is CAplus.

The purpose of the research is to compare the analgesia effect and the safety of Flurbiprofen Axetil (FA) and Parecoxib Sodium (PS) after posterior lumbar fusion surgery. 90 Cases of patients undergoing internal fixation of lumbar spine were randomly assigned to 3 groups:those in Group A(n=30) received 100 mg of FA; those in Group B (n=30) received 40 mg of PS and those in Group C received saline. The VAS scores of 2, 6, 12, 24, 48, 72 h after operation and the dose of tramadol hydrochloride (TH) used and the side effect was recorded resp. Group A and B had significantly better analgesic effect than Group C(P<0.05). Group A and B had lower average dose of TH than Group C (P<0.05). The VAS scores in Group A was lower than that in Group B in 2 h after the surgery. The VAS scores after the surgery showed no significant difference between Group A and B in 6 , 12, 24 h after the surgery. The VAS scores in Group A was higher than that in Group B in 48, 72 h after the surgery. Both PS and FA can alleviate postoperative pain and have fewer adverse reactions.

Shiyong Yixue Zazhi published new progress about 198470-85-8. 198470-85-8 belongs to isoxazole, auxiliary class Immunology/Inflammation,COX, name is Sodium ((4-(5-methyl-3-phenylisoxazol-4-yl)phenyl)sulfonyl)(propionyl)amide, and the molecular formula is C19H17N2NaO4S, Application In Synthesis of 198470-85-8.

Referemce:
https://en.wikipedia.org/wiki/Isoxazole,
Isoxazole | C3H3NO – PubChem

Li, Mei published the artcileProtective effect of parecoxib sodium against ischemia reperfusion-induced intestinal injury, COA of Formula: C19H17N2NaO4S, the publication is Molecular Medicine Reports (2021), 24(5), 776, database is CAplus and MEDLINE.

Ischemia reperfusion (I/R)-induced intestinal injury is a pathophysiol. process leading to oxidative stress and inflammatory responses, and revealing its underlying mechanisms is essential for developing therapeutic strategies. Cyclooxygenase (COX) has been reported to be involved in I/R injury. Parecoxib sodium, a selective inhibitor for COX-2, exerts protective effects, such as reducing I/R-induced injuries in the heart, kidney and brain. However, the potential role of parecoxib sodium in protecting the small intestine against I/R-induced injury has rarely been investigated. Therefore, the aim of the present study was to elucidate the effects and potential mechanisms of parecoxib sodium in I/R-induced intestinal injury. In total, 60 Sprague-Dawley rats were randomly divided into four groups: Control (sham operation) group, intestinal I/R group, 10 mg/kg parecoxib sodium-pre-treated I/R (I/R + Pare/10) group and the 20 mg/kg parecoxib sodium-pre-treated I/R (I/R + Pare/20) group. A regular I/R model was established to induce the intestinal injury in rats. Parecoxib sodium at 10 or 20 mg/kg was i.p. administered into rats in both I/R + Pare groups once daily for 5 consecutive days prior to ischemia. Blood samples and small intestinal tissues were collected at 2 h after reperfusion. Changes in the levels of malondialdehyde, nitric oxide, interleukin (IL)-1β, IL-8, intercellular cell adhesion mol.-1 and IL-10, as well as the total antioxidant capacity were determined using ELISA, as were the activities of superoxidase dismutase and myeloperoxidase. Furthermore, the protein expression levels of total caspase-3, cleaved caspase-3, Bcl-2 and Bax were examined via western blot anal. In addition, the daily survival rate post-reperfusion was examined for 7 days. It was revealed that parecoxib sodium increased the levels of antioxidants and suppressed the intestinal oxidative injury induced by I/R. Moreover, parecoxib sodium downregulated the expression levels of the proinflammatory factors, but upregulated the expression levels of anti-inflammatory factors. The results also demonstrated that parecoxib sodium attenuated I/R-induced apoptosis and increased the survival rate of rats. Thus, administration of parecoxib sodium prior to intestinal I/R attenuated intestinal injury and increased the rat survival rate by inhibiting I/R-induced inflammation, oxidative stress and apoptosis.

Molecular Medicine Reports published new progress about 198470-85-8. 198470-85-8 belongs to isoxazole, auxiliary class Immunology/Inflammation,COX, name is Sodium ((4-(5-methyl-3-phenylisoxazol-4-yl)phenyl)sulfonyl)(propionyl)amide, and the molecular formula is C19H17N2NaO4S, COA of Formula: C19H17N2NaO4S.

Referemce:
https://en.wikipedia.org/wiki/Isoxazole,
Isoxazole | C3H3NO – PubChem

Liu, Wen-jie published the artcilePaclitaxel-induced lung injury and its amelioration by parecoxib sodium, Application of Sodium ((4-(5-methyl-3-phenylisoxazol-4-yl)phenyl)sulfonyl)(propionyl)amide, the publication is Scientific Reports (2015), 12977, database is CAplus and MEDLINE.

To investigate the mechanism of paclitaxel-induced lung injury and its amelioration by parecoxib sodium. In this study, rats were randomly divided into: the control group (Con); the paclitaxel chemotherapy group (Pac); the paclitaxel+ parecoxib sodium intervention group (Pac + Pare); and the parecoxib sodium group (Pare). We observed changes in alveolar ventilation function, alveolar-capillary membrane permeability, lung tissue pathol. and measured the levels of inflammatory cytokines and cyclooxygenase-2 (Cox-2) in lung tissue, the expression of tight junction proteins (Zo-1 and Claudin-4). Compared with the Con group, the lung tissue of the Pac group showed significantly increased expression of Cox-2 protein (p < 0.01), significant lung tissue inflammatory changes, significantly increased expression of inflammatory cytokines, decreased expression of Zo-1 and Claudin-4 proteins (p < 0.01), increased alveolar-capillary membrane permeability (p < 0.01), and reduced ventilation function (p < 0.01). Notably, in Pac + Pare group, i.p. injection of parecoxib sodium led to decreased Cox-2 and ICAM-1 levels and reduced inflammatory responses, the recovered expression of Zo-1 and Claudin-4, reduced level of indicators reflecting the high permeability state, and close-to-normal levels of ventilation function. Intervention by the Cox-2-specific inhibitor parecoxib sodium can block this damage.

Scientific Reports published new progress about 198470-85-8. 198470-85-8 belongs to isoxazole, auxiliary class Immunology/Inflammation,COX, name is Sodium ((4-(5-methyl-3-phenylisoxazol-4-yl)phenyl)sulfonyl)(propionyl)amide, and the molecular formula is C19H17N2NaO4S, Application of Sodium ((4-(5-methyl-3-phenylisoxazol-4-yl)phenyl)sulfonyl)(propionyl)amide.

Referemce:
https://en.wikipedia.org/wiki/Isoxazole,
Isoxazole | C3H3NO – PubChem

Qin, Zijian published the artcileClassification of Cyclooxygenase-2 Inhibitors Using Support Vector Machine and Random Forest Methods, Synthetic Route of 198470-85-8, the publication is Journal of Chemical Information and Modeling (2019), 59(5), 1988-2008, database is CAplus and MEDLINE.

This work reports the classification study conducted on the biggest COX-2 inhibitor data set so far. Using 2925 diverse COX-2 inhibitors collected from 168 pieces of literature, we applied machine learning methods, support vector machine (SVM) and random forest (RF), to develop 12 classification models. The best SVM and RF models resulted in MCC values of 0.73 and 0.72, resp. The 2925 COX-2 inhibitors were reduced to a data set of 1630 mols. by removing intermediately active inhibitors, and 12 new classification models were constructed, yielding MCC values above 0.72. The best MCC value of the external test set was predicted to be 0.68 by the RF model using ECFP_4 fingerprints. Moreover, the 2925 COX-2 inhibitors were clustered into eight subsets, and the structural features of each subset were investigated. We identified substructures important for activity including halogen, carboxyl, sulfonamide, and methanesulfonyl groups, as well as the aromatic nitrogen atoms. The models developed in this study could serve as useful tools for compound screening prior to laboratory tests.

Journal of Chemical Information and Modeling published new progress about 198470-85-8. 198470-85-8 belongs to isoxazole, auxiliary class Immunology/Inflammation,COX, name is Sodium ((4-(5-methyl-3-phenylisoxazol-4-yl)phenyl)sulfonyl)(propionyl)amide, and the molecular formula is C19H17N2NaO4S, Synthetic Route of 198470-85-8.

Referemce:
https://en.wikipedia.org/wiki/Isoxazole,
Isoxazole | C3H3NO – PubChem

Bi, Yan published the artcileAnalysis of influence of parecoxib sodium on recovery period after laparoscopic cholecystectomy under fast track anesthesia with remifentanil later, HPLC of Formula: 198470-85-8, the publication is Yixue Zongshu (2015), 21(10), 1890-1892, database is CAplus.

Objective To observe the influence of parecoxib sodium on the recovery period after laparoscopic cholecystectomy (LC) under fast track anesthesia with remifentanil. Methods A total of 114 cases of gallstone admitted in Shaoguan First People’s Hospital from Mar. 2013 to Feb. 2014 were divided into the control group (56 cases) and observation group (58 cases) by random number table method. Patients in both groups received LC treatment under fast track anesthesia with remifentanil, patients in the observation group received injection of 5 mL saline and parecoxib sodium mixture 20 min before anesthesia, while patients in the control group received injection of 5 mL saline. The awake and extubation time of the two groups was recorded, while changes of mean pulsating pressure (MAP), pulse oxygen saturation (SpO₂), heart rate and other indicators of recovery period were observed at the time points of 5 min before extubation (T₁), extubation time (T₂), 5 min after extubation (T₃) and 15 min after extubation (T₄), besides, Ramsay sedation and VAS pain scores were recorded, incidences of restlessness, arrhythmia and other adverse reactions were observed Results MAP, heart rate of the observation group only fluctuated at T₂, then leveled off; MAP, heart rate of the control group significantly fluctuated after T1, there was statistically significant difference between the two groups (P<0.05). Postoperative agitation score and VAS pain score of the observation group were (1.8±0.9) scores and (2.3±1.2) scores, significantly lower than those of the control group (3.4±1.0) scores and (4.2±1.3) scores], while Ramsay sedation score was higher than the control group [(3.5±1.1) scores vs (1.7±0.8) scores], the difference was statistically significant (P<0.01). The incidence of agitation of the observation group was lower than the control group [10.3% (6/58) vs 30.4% (17/56)], the difference was statistically significant (P<0.01). Conclusion Application of parecoxib sodium to induce the fast track anesthesia with remifentanil before LC can stable the hemodynamics, reduce postoperative pain and stress response, with fewer adverse reactions, therefore, it is worth for clin. promotion.

Yixue Zongshu published new progress about 198470-85-8. 198470-85-8 belongs to isoxazole, auxiliary class Immunology/Inflammation,COX, name is Sodium ((4-(5-methyl-3-phenylisoxazol-4-yl)phenyl)sulfonyl)(propionyl)amide, and the molecular formula is C19H17N2NaO4S, HPLC of Formula: 198470-85-8.

Referemce:
https://en.wikipedia.org/wiki/Isoxazole,
Isoxazole | C3H3NO – PubChem

Yang, Shuyi published the artcileParecoxib shortens the duration of acute postoperative pain after laparoscopic-assisted vaginal hysterectomy, Recommanded Product: Sodium ((4-(5-methyl-3-phenylisoxazol-4-yl)phenyl)sulfonyl)(propionyl)amide, the publication is Frontiers in Pharmacology (2019), 689, database is CAplus and MEDLINE.

The effect of parecoxib sodium on the duration and severity of acute postoperative pain after laparoscopic-assisted vaginal hysterectomy has been inadequately studied. This randomized, controlled trial compared the effects of parecoxib, methylprednisolone, and placebo on the duration of acute postoperative pain after elective laparoscopicassisted vaginal hysterectomy. Ninety-four eligible patients were randomized to three groups [parecoxib sodium 40 mg (Group P), methylprednisolone 1 mg/kg (Group M), and saline (Group S)]. The duration of pain during coughing [median (interquartile range)] was significantly lower in Group P than in Group M or Group S [26.0 (5.8-48.0) vs. 48.0 (30.0-55.5) vs. 48.0 (36.0-58.5) h; p = 0.025]. The duration of pain during rest was also significantly lower in Group P than in Group M or Group S [5.5 (3.8-21.0) vs. 24.0 (6.0- 28.0) vs. 22.0 (5.8-36.0) h; p = 0.009]. Compared with those in Group M and Group S, the patients in Group P reported less intense visceral pain during coughing at 12 ( p = 0.050) and 24 h ( p = 0.009) as well as at rest at 12 h ( p = 0.008). Compared with those in Group P and Group S, the patients in Group M showed lower serum C-reactive protein levels and higher blood glucose levels after surgery. No differences were noted in nausea, vomiting, length of hospital stay, wound infection, and delayed wound healing among the groups. Thus, parecoxib sodium reduces the duration and intensity of acute postoperative pain after laparoscopic-assisted vaginal hysterectomy.

Frontiers in Pharmacology published new progress about 198470-85-8. 198470-85-8 belongs to isoxazole, auxiliary class Immunology/Inflammation,COX, name is Sodium ((4-(5-methyl-3-phenylisoxazol-4-yl)phenyl)sulfonyl)(propionyl)amide, and the molecular formula is C12H16N2O2, Recommanded Product: Sodium ((4-(5-methyl-3-phenylisoxazol-4-yl)phenyl)sulfonyl)(propionyl)amide.

Referemce:
https://en.wikipedia.org/wiki/Isoxazole,
Isoxazole | C3H3NO – PubChem

Zhang, Jin-li published the artcileInfluence of preemptive analgesia with parecoxib sodium on stress reaction and inflammation reaction in elderly patients after abdominal operation, HPLC of Formula: 198470-85-8, the publication is Hainan Yixueyuan Xuebao (2014), 20(6), 854-856, database is CAplus.

Objective: To investigate the effect of preemptive analgesia with parecoxib sodium on stress reaction and inflammation reaction in elderly patients after abdominal operation. Methods: A total of 60 cases aged 60-75 years old were randomly divided into observation group and control group by half. They received i.v. injection of parecoxib sodium 40 mg (diluted with saline to 4 mL) 15 min before anesthesia in observation group. Patients in control group were injected with saline 4 mL. VAS score was measured 1 h, 6 h, 12 h, 24 h after surgery. 6 ML venous blood was extracted at 5 min before anesthesia (T₀). 1 H after operation (T₁), 6 h after operation (T₂), 12 h after operation (T₃), 24 h after operation (T₄) to determine cortisol (Cor) and interleukin-6 (IL-6) concentration Result: VAS score in observation group at different time points was significantly lower than those of control group (P < 0.01); Cor and IL-6 at T₁, T₂, T₃, T₄ were significantly lower than those in the control group (P < 0.01). Conclusion: preemptive analgesia with parecoxib sodium can effectively relieve postoperative pain in elderly patients with abdominal operation. It can reduce the stress response, and inhibit the release of inflammatory mediators.

Hainan Yixueyuan Xuebao published new progress about 198470-85-8. 198470-85-8 belongs to isoxazole, auxiliary class Immunology/Inflammation,COX, name is Sodium ((4-(5-methyl-3-phenylisoxazol-4-yl)phenyl)sulfonyl)(propionyl)amide, and the molecular formula is C8H4FNO3, HPLC of Formula: 198470-85-8.

Referemce:
https://en.wikipedia.org/wiki/Isoxazole,
Isoxazole | C3H3NO – PubChem

Li, Jian-yu published the artcileEffects of dexmedetomidine on postoperative mechanical pain threshold in patients undergoing laparoscopic cholecystectomy under continuous infusion of remifentanil, Quality Control of 198470-85-8, the publication is Shiyong Yixue Zazhi (2015), 31(21), 3574-3577, database is CAplus.

This paper is to identify whether dexmedetomidine can prevent postoperative hyperalgesia of patients undergoing laparoscopic cholecystectomy. One hundred and twenty patients undergoing elective laparoscopic cholecystectomy were randomly divided into three groups: dexmedetomidine group (group D, patients receiving dexmedetomidine), parecoxib sodium group (group P, patients receiving parecoxib sodium) and control group (group C). Mech. pain thresholds on periincisional area and VAS score were recorded 2, 4, 8, 12, 24, 48 h after surgery. Mech. pain thresholds in group C at 2, 4, 8, 12, 24, 48 h after operation decreased significantly compared with those before operation(P<0.01) but those in group D had no significant difference, and the thresholds in group P at 4 h, 8 h had no significant decrease. Compared with those in group C, mech. pain thresholds in group D increased at 2, 4, 8, 12, 24, 48 h after operation(P<0.05), and those in group P increased at 4 h and 8 h after operation(P<0.05). Compared with those in group P, mech. pain thresholds in group D increased at 12, 24, 48 h after operation. Compared with preoperative VAS values, values were significantly increased in every group(P<0.05). Furthermore, postoperative VAS values had no correlation with mech. pain threshold in each group and the incidence of adverse reactions had no significant difference among three groups(P>0.05). Dexmedetomidine can prevent postoperative hyperalgesia in patients undergoing laparoscopic cholecystectomy.

Shiyong Yixue Zazhi published new progress about 198470-85-8. 198470-85-8 belongs to isoxazole, auxiliary class Immunology/Inflammation,COX, name is Sodium ((4-(5-methyl-3-phenylisoxazol-4-yl)phenyl)sulfonyl)(propionyl)amide, and the molecular formula is C19H17N2NaO4S, Quality Control of 198470-85-8.

Referemce:
https://en.wikipedia.org/wiki/Isoxazole,
Isoxazole | C3H3NO – PubChem

Fu, Weihua published the artcileEfficacy and Safety of Parecoxib/Phloroglucinol Combination Therapy Versus Parecoxib Monotherapy for Acute Renal Colic: A Randomized, Double-Blind Clinical Trial, Recommanded Product: Sodium ((4-(5-methyl-3-phenylisoxazol-4-yl)phenyl)sulfonyl)(propionyl)amide, the publication is Cell Biochemistry and Biophysics (2014), 69(1), 157-161, database is CAplus and MEDLINE.

To investigate whether the addition of phloroglucinol to parecoxib could improve the efficacy in patients with acute renal colic. Patients of acute renal colic were randomly allocated to receive i.v. Parecoxib 40 mg plus placebo or Parecoxib 40 mg plus phloroglucinol 80 mg, resp. Pain intensity was recorded using a visual analog scale (VAS) before drug administration and 5, 15, 30, 60, and 120 min after treatment start. The primary outcome was the mean pain intensity difference (PID) at each checkpoint and the effectiveness of drugs (≥50 ^decrease in VAS score at the end checkpoint). The need for rescue analgesics and the incidence of adverse effects were considered as secondary outcome of the study. Among 236 patients enrolled in the study, 119 patients received i.v. parecoxib plus placebo and 114 patients received i.v. parecoxib plus phloroglucinol, the remaining 3 patients given up treatment. Baseline demographics were similar between two groups. There are significant differences in the PID at 15 and 30 min between two groups (P_15 min = 0.011, P_30 min = 0.013). Rescue analgesics were required by 17 patients (14.3 )̂ receiving parecoxib, 7 patients (6.1 )̂ receiving parecoxib plus phloroglucinol (P = 0.041). There were no differences in PID at other checkpoints between two groups, as well as in the incidence of adverse events and the drug effectiveness. Parecoxib in combination with phloroglucinol for acute renal colic has a faster action, also reduces the demand of rescue analgesics.

Cell Biochemistry and Biophysics published new progress about 198470-85-8. 198470-85-8 belongs to isoxazole, auxiliary class Immunology/Inflammation,COX, name is Sodium ((4-(5-methyl-3-phenylisoxazol-4-yl)phenyl)sulfonyl)(propionyl)amide, and the molecular formula is C19H17N2NaO4S, Recommanded Product: Sodium ((4-(5-methyl-3-phenylisoxazol-4-yl)phenyl)sulfonyl)(propionyl)amide.

Referemce:
https://en.wikipedia.org/wiki/Isoxazole,
Isoxazole | C3H3NO – PubChem

Zhu, Yang-Zi published the artcileParecoxib prevents early postoperative cognitive dysfunction in elderly patients undergoing total knee arthroplasty: A double-blind, randomized clinical consort study, Product Details of C19H17N2NaO4S, the publication is Medicine (Philadelphia, PA, United States) (2016), 95(28), e4082, database is CAplus and MEDLINE.

Background: Trial design neuroinflammation and postoperative pain after surgery are increasingly reported in association with postoperative cognitive dysfunction (POCD). Parecoxib, a selective cyclooxygenase (COX)-2 inhibitor, is used for postoperative analgesia for its potent anti-inflammatory and analgesic effects. This study aimed to evaluate parecoxib’s effects on POCD in elderly patients undergoing total knee arthroplasty. Methods: Around 134 elderly patients undergoing total knee arthroplasty were randomly divided into parecoxib (group P) and control (groupC) groups, and treated with parecoxib sodium and saline, resp., shortly after induction of general anesthesia and 12-h postsurgery, resp. Perioperative plasma IL-1β, IL-6, TNF-α, and C-reactive protein (CRP) levels were measured. Postoperative pain was assessed following surgery. Neuropsychol. tests were performed before surgery, and 1 wk and 3 mo postoperation. Results: POCD incidence in group P was significantly lower compared with that of group C at 1 wk after surgery (16.7% vs 33.9%; P<0.05); no significant difference was found between groups C and P at 3-mo follow-up (9.7% vs 6.7%). Compared with group C values, visual analog pain scale (VAS) scores at 3, 6, and 12h after surgery were significantly lower in group P(P<0.05). Plasma IL-1β, IL-6, and TNF-α levels were lower in group P than in group C after the operation (P<0.05). No significant difference in the plasma CRP level was found between groups P and C. Conclusions: Parecoxib sodium decreases POCD incidence after total knee arthroplasty in elderly patients and may explain how this drug suppresses inflammation and acute postoperative pain caused by surgical trauma.

Medicine (Philadelphia, PA, United States) published new progress about 198470-85-8. 198470-85-8 belongs to isoxazole, auxiliary class Immunology/Inflammation,COX, name is Sodium ((4-(5-methyl-3-phenylisoxazol-4-yl)phenyl)sulfonyl)(propionyl)amide, and the molecular formula is C38H74Cl2N2O4, Product Details of C19H17N2NaO4S.

Referemce:
https://en.wikipedia.org/wiki/Isoxazole,
Isoxazole | C3H3NO – PubChem